title: Antiplatelet therapy to prevent cardiovascular events and mortality in patients with intermittent claudication.
abstract: OBJECTIVE
  Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality?
  
  
  CONCLUSIONS
  In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.
authors: Department of Vascular Surgery, James Cook University Hospital, Marton Road, Middlesbrough, Cleveland, TS4 3BW England. pwong23@hotmail.com
authors: Peng Foo
authors: PF
authors: Wong
authors: Lee-Yee
authors: LY
authors: Chong
authors: Gerard
authors: G
authors: Stansby
mesh_terms: D002318:Cardiovascular Diseases / Q000401:mortality* / Q000517:prevention & control*; D002423:Cause of Death; D019317:Evidence-Based Medicine; D006801:Humans; D007383:Intermittent Claudication / Q000150:complications* / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic
chemical_list: D010975:Platelet Aggregation Inhibitors